No Prescription |
 |
 | ||
|
Niftran Macrobid |
|
| ||
No Prescription » Prescription Drugs 12 » Niftran Macrobid This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for viral infections (e.g. common cold flu). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (e.g. kidney infections such as pyelonephritis or perinephric abscesses). Buy Niftran Macrobid and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Niftran Macrobid: Product Type: Prescription Drugs 12 Niftran (Macrobid Macrodantin Generic Nitrofurantoin) Niftran (Macrobid Macrodantin Generic Nitrofurantoin) Macrobid Macrodantin Generic Nitrofurantoin 100mg Macrobid Macrodantin Generic Nitrofurantoin Niftran
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
